Malignant Mesothelioma Market Size Expected to Hit US$ 1,164.9 Million by 2034, Exhibiting 7.6% CAGR: Fact.MR Analysis

The size of the global malignant mesothelioma market is anticipated to be US$ 561.9 million in 2024. The market is expected to grow at a promising CAGR of 7.6% to reach sales of US$ 1,164.9 million by 2034.

Major players offering malignant mesothelioma therapeutics are likely to utilize technologies such as artificial intelligence, 3D printing, and nanotechnology for enhanced production efficiency. Thus fulfilling the growing demand for drugs/medications to increase the patient's life expectancy.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9554

Region-wise Insights

According to recent market forecasts, the North America malignant mesothelioma market is anticipated to capture a whopping value share of 37% in 2024. The revenue generated by this regional market is forecast to increase from US$ 208 million in 2024 to US$ 389 million by 2034. Demand for malignant mesothelioma drugs is estimated to record a 6.5% CAGR for this period.

As per latest market forecasts, the Latin America market for malignant mesothelioma is likely to achieve a meager share of 11.9% in 2024. The rate of adoption of malignant mesothelioma therapeutics, however, is likely to experience accelerated growth. Over the period 2024-2034, this regional market is anticipated to register a 9.4% CAGR.

Segment-wise Insights

The pemetrexed and combination drug category has a top position, with a market share of 49.8% in 2024. Sales of pemetrexed and combination drugs are estimated to generate US$ 280.0 million in revenue during 2024. Achieving a purchase rate of 7.8% CAGR, pemetrexed and combination drugs are expected to reach US$ 596.0 million by 2034. Growth in this segment depends on increasing clinical trials by major players and associated organizations to find more efficient pemetrexed and combination drugs.

Competitive Landscape

Market leaders in the malignant mesothelioma market are placing investments in research and development programs for new mesothelioma therapies, including immunotherapy medicines, targeted agents, and combination therapies, in order to confer substantial advantages. Market leaders are also refining their current drugs through formulations to eliminate their side effects, enhance their efficacy, and create improved delivery systems for successful differentiation.

Industry players are developing and selling sophisticated diagnostic equipment to identify malignant mesothelioma in order to increase patient outcomes and market size. Alongside, the players are venturing into new geographies where the rate of disease incidence is increasing. At present, targeted markets are Latin America and Asia Pacific, along with mature markets.

Market players are also partnering with patient advocacy organizations, research centers, and other healthcare providers to gain wider reach, enhance brand reputation, and enhance research efficiency. Acquisitions and mergers with smaller or similar-sized firms are also promoting market consolidation.

Recent Trends in the Malignant Mesothelioma Market

In June 2023, Amneal Pharmaceuticals, Inc. reported that the company had acquired 505(b)(2) New Drug Application (NDA) approval from the United States FDA. It is the initial and sole pre-dilition, pre-reconstitution, ready-to-use demonstration of pemetrexed for injection and has no need to be diluted or refrigerated. This injectable is indicated in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer.
In May 2023, scientists concluded that quinacrine, being an antimalarial medication when used on mesothelioma cells, has the ability to protect aggressive tumors from growing new blood vessels and leading to cell death.
In April of 2023, the FDA submitted fast-track designation to SynKIR-110, a new T-Cell therapy, for treating patients with mesothelioma. It's a significant achievement for the firm as it recognizes the efforts of the company in introducing the life-saving drug to patients in need of new options.
In October 2020, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for treating mesothelioma. The drug combination is employed as initial treatment for adults with malignant pleural mesothelioma. In 16 years, it is the first drug regimen which has been approved for mesothelioma.

Browse Full Report: https://www.factmr.com/report/malignant-mesothelioma-market

Segmentation of Malignant Mesothelioma Market Research

By Drug Type:
Pemetrexed and combination
Cisplatin and combination
Carboplatin and combination
Gemcitabine and combination
Vinorelbine and combination
Others combinations
By Route of Administration:
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
By Region:
North America
Europe
Latin America
East Asia
South Asia and Oceania
The Middle East and Africa

Check out More Related Studies Published by Fact.MR:

Diabetes Management Software Market
https://www.factmr.com/report/431/diabetes-management-software-market

Breast Pumps Market
https://www.factmr.com/report/4690/breast-pumps-market

Medical Holography Market
https://www.factmr.com/report/4798/medical-holography-market

Shoulder Arthroplasty Market
https://www.factmr.com/report/shoulder-arthroplasty-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.